Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mammalian cells treated with low concentrations of
phospholipase C
become permeable to the protein toxin
alpha-sarcin
. A similar permeabilization is not induced upon treatment with other lipases such as phospholipase A2, sphingomyelinase, or cholesterol esterase. Concentrations of 10 micrograms/ml
alpha-sarcin
almost completely blocked translation in HeLa cells treated with 0.3 U/ml
phospholipase C
(PL-C) for 1 h. In contrast, 200 micrograms/ml of
alpha-sarcin
had no effect at all on protein synthesis in untreated cells. Other macromolecules such as horseradish peroxidase and luciferase also enter into cells if they are treated with
phospholipase C
. This permeabilization method is fully reversible. As soon as 5 min after PL-C removal, the cells become impermeable to
alpha-sarcin
. Other metabolites such as uridine nucleotides are partially released after PL-C incubation, whereas the content of 86Rb+ remains at control levels, probably because the Na+/K+ ATPase activity increases.
...
PMID:Exogenous phospholipase C permeabilizes mammalian cells to proteins. 313 47
